论文部分内容阅读
目的:评价阿奇霉素序贯疗法治疗小儿支原体肺炎患者的临床疗效及其安全性。方法:选取2015年5月—2016年5月间收治的支原体肺炎患儿80例临床资料,将其按照数字表法平均分为对照组(n=40例)和观察组(n=40例);对照组患者给予乳酸红霉素治疗,观察组患儿则给予阿奇霉素序贯疗法治疗。结果:观察组患儿治疗后的各项临床症状(体温复常时间、住院时间以及咳嗽、啰音复常时间)均明显优于对照组(P<0.05),总有效率为97.50%也明显高于对照组为85.00%(P<0.05),不良反应的发生率为2.50%则明显低于对照组为15.00%(P<0.05)。结论:采用阿奇霉素序贯疗法治疗小儿支原体肺炎患者,不仅能提高患儿的治疗效果,并且降低了不良反应的发生率。
Objective: To evaluate the clinical efficacy and safety of sequential treatment of azithromycin in children with mycoplasma pneumonia. Methods: The clinical data of 80 cases of mycoplasma pneumonia admitted from May 2015 to May 2016 were selected and divided into control group (n = 40) and observation group (n = 40) according to the digital table method. ; Control group patients given erythromycin lactate treatment, the observation group was given azithromycin sequential therapy. Results: All the clinical symptoms (body temperature recovery time, hospitalization time, cough and auscultation time) in the observation group were significantly better than those in the control group (P <0.05), and the total effective rate was 97.50%. (P <0.05). The incidence of adverse reactions was 2.50%, which was significantly lower than that of the control group (15.00%, P <0.05). Conclusion: Sequential azithromycin treatment of children with mycoplasma pneumonia patients, not only can improve the therapeutic effect in children, and reduce the incidence of adverse reactions.